A patient's OB started her on fluoxetine, but I know sertraline is preferred. What do I do?

Provide accurate information to the patient if she asks: "Sertraline is generally the preferred option in breastfeeding patients because it has the most data and the lowest infant exposure. Your OB may have had specific reasons for choosing fluoxetine -- it's worth asking about your options." Do not instruct the patient to stop her medication. The clinical decision belongs to the prescriber.

Should I screen for PPD as an IBCLC?

Yes. The Edinburgh Postnatal Depression Scale (EPDS) is validated for use by non-mental-health providers and is appropriate in lactation visit settings. EPDS score 10 or above warrants referral. For a patient whose distress clearly exceeds the clinical feeding situation, you do not need to wait for a formal score to provide a referral.

My patient is worried about infant effects from her medication. What should I watch for?

SSRIs at standard doses rarely produce notable effects in breastfed infants. Parents can monitor for: unusual sedation, difficulty feeding, irritability significantly beyond baseline, or changes in sleep patterns. These are uncommon with first-line agents like sertraline but appropriate to mention. If the parent observes any of these, consulting the prescriber and the pediatrician is the correct path.

What about patients on benzodiazepines for anxiety?

Benzodiazepine use in breastfeeding patients requires individual clinical assessment. Most benzos transfer into breast milk at varying levels. Short-acting agents and lower doses carry lower infant exposure risk. LactMed has current data for individual agents. The same principle applies: the prescribing decision belongs to the treating provider; your role is to provide accurate information and facilitate the conversation.

Antidepressants & Breastfeeding Safety | Clinical Reference for IBCLCs & OBs

The Clinical Context

Postpartum depression affects approximately 1 in 5 postpartum women. Antidepressants, particularly SSRIs, are a primary treatment modality. Many patients on antidepressants are also breastfeeding, or are considering breastfeeding, or are considering stopping medication in order to breastfeed.

IBCLCs, OBs, and pediatricians encounter this question regularly. Patients ask because they are trying to make an informed decision, because they have received inconsistent information from different providers, or because they have read something alarming online. Accurate, evidence-based guidance is one of the most direct interventions you can make in this situation.

This article provides the clinical framework. For decision-making on individual patients, LactMed (NIH) and MotherToBaby are the authoritative sources to consult and to cite to patients.

---

The Risk-Benefit Framework

Before reviewing specific agents, the overarching clinical principle: untreated postpartum depression has documented, significant negative effects on the breastfeeding patient and her infant.

Effects of untreated PPD on breastfeeding: As summarized in the clinical literature, PPD is associated with lower breastfeeding initiation rates, earlier cessation, reduced exclusive breastfeeding, and lower feeding satisfaction and quality. A depressed mother and a medicated mother are not equivalent outcomes for the infant.

Effects of untreated PPD on infant development: PPD affects mother-infant bonding, which has downstream effects on infant cognitive and emotional development, attachment security, and later behavioral outcomes. These effects are independent of breastfeeding method.

The relative infant dose metric: Medication safety in breastfeeding is primarily evaluated via the relative infant dose (RID), which represents the infant's weight-adjusted exposure relative to the maternal dose. An RID below 10 percent is generally considered acceptable. Most SSRIs used in PPD treatment are well below this threshold.

The risk-benefit calculation almost universally favors treating PPD in breastfeeding patients when clinical indication is present.

---

SSRI Safety Profiles

Sertraline (Zoloft)

Sertraline is the SSRI with the most extensive breastfeeding safety data and the most favorable profile.

RID: 0.5 to 3 percent
Infant serum levels: Typically undetectable or very low in most studies
Clinical recommendation: First-line SSRI in breastfeeding patients per most perinatal clinical guidelines, including ACOG and the Academy of Breastfeeding Medicine
LactMed summary: Acceptable to use during breastfeeding; one of the best-studied SSRIs in this context

Escitalopram (Lexapro)

Escitalopram is generally considered second-line after sertraline.

RID: Approximately 3 to 8 percent
Infant serum levels: Some reports of detectable levels, particularly at higher maternal doses; most infants tolerate well
Clinical recommendation: Acceptable in breastfeeding; monitor infant for sedation, feeding changes, or irritability at higher maternal doses
LactMed summary: Use acceptable; sertraline preferred if starting new

Paroxetine (Paxil)

RID: 1 to 3 percent
Infant serum levels: Generally undetectable or very low
Note: Less commonly selected as first-line due to significant discontinuation syndrome risk in the mother (abrupt stopping produces severe withdrawal symptoms), which complicates management in the postpartum period
LactMed summary: Acceptable; discontinuation effects are a clinical consideration in prescribing decisions

Fluoxetine (Prozac)

Fluoxetine requires more careful consideration due to its active metabolite.

RID: 2 to 15 percent (range is wide due to norfluoxetine accumulation)
Infant serum levels: Higher than other SSRIs due to long half-life of norfluoxetine; detected in infant serum in some studies
Clinical recommendation: Not first-line for new starts in breastfeeding patients; if a patient has responded well to fluoxetine previously, continuation is generally preferred over switching (destabilizing a patient who is responding is a clinical risk)
LactMed summary: Potential for infant accumulation; consider alternatives for new starts

Citalopram (Celexa)

RID: Approximately 3.5 to 5 percent
Infant serum levels: Detectable at low levels in some studies; some case reports of infant irritability at higher maternal doses
Clinical recommendation: Generally acceptable; escitalopram is the pharmacologically cleaner option if an escitalopram/citalopram choice exists

---

SNRIs and Other Agents

Venlafaxine (Effexor) and duloxetine (Cymbalta)

Both SNRIs have less breastfeeding safety data than the established SSRIs, but available data is generally reassuring.

Venlafaxine RID: approximately 6 to 8 percent; active metabolite O-desmethylvenlafaxine also transfers; infant monitoring appropriate
Duloxetine RID: low (less than 1 percent in most studies); limited data overall
Both are considered acceptable when clinically indicated; LactMed and MotherToBaby should be consulted for current data

Bupropion (Wellbutrin)

Used as an alternative in patients with concerns about SSRI side effects or in combination.

Limited data; low RID (approximately 0.2 percent) but active metabolite hydroxybupropion has been detected in infant serum
One case report of possible seizure in a breastfed infant; causality not established but noted in the literature
Generally considered acceptable in clinical practice; individual risk-benefit discussion appropriate

Brexanolone (Zulresso) and zuranolone (Zurzuvae)

These neuroactive steroid agents are FDA-approved specifically for PPD.

Brexanolone: intravenous administration, 60-hour infusion; breastfeeding during treatment is not recommended due to insufficient data; pumping and discarding during treatment with resumption after is the recommended approach
Zuranolone: oral, 14-day course; limited breastfeeding data; prescribing information recommends against breastfeeding during treatment and for one week after the last dose

Both agents are significant additions to the PPD treatment landscape. IBCLCs working with patients who may be candidates for these treatments should be aware that breastfeeding interruption is part of the current clinical guidance.

---

What to Tell Patients

For a patient currently on medication who is asking about breastfeeding safety

"The medication you're on has been studied in breastfeeding patients extensively. The amount that passes into breast milk is very small -- it's one of the best-studied medications in this category. The research shows it's generally safe for nursing infants. The more important consideration is that treating your depression is good for your health, for your breastfeeding relationship, and for your baby's development. A depressed mother and a medicated mother are not equivalent outcomes for your baby."

For a patient who wants to stop medication to breastfeed

This situation requires direct intervention.

"I want to make sure you've had a chance to discuss this with your prescriber before making any change. Stopping this type of medication on your own carries real risks -- including that your symptoms could return, which would actually make breastfeeding harder, not easier. Can we get you connected with your prescriber to have that conversation first?"

Your role in this situation:

Listen to the patient's reasoning without dismissing it
Provide accurate information about medication safety (it is likely safe; the infant exposure is low)
Refer to the prescriber for any decision about tapering or stopping
Do not actively encourage stopping medication to breastfeed -- the clinical harm from PMAD recurrence or untreated depression outweighs the benefit of medication-free breastfeeding in almost all cases

For a patient asking for data

"The most reliable source is LactMed, which is run by the NIH. You can search your specific medication and get the current clinical data. MotherToBaby is another good resource -- they have a hotline you can call. I'd also recommend a conversation with your prescriber so you can review your specific situation."

---

Authoritative References

LactMed (Drugs and Lactation Database): drugs.ncbi.nlm.nih.gov/lactmed -- free, current, evidence-graded medication safety data for breastfeeding
MotherToBaby: mothertobaby.org -- patient and provider resource; phone consultation line available
Academy of Breastfeeding Medicine Protocol #18: Clinical protocol on use of antidepressants in breastfeeding mothers
ACOG Practice Bulletin on Postpartum Depression: includes pharmacological treatment guidance

Do not use general drug reference sources (PDR, standard pharmacy references) for lactation-specific guidance. These sources typically lack RID data and lactation-specific safety grading and may overstate risk based on package insert language.

---

Medication-Safe Breastfeeding for Patients on Antidepressants